ZPC 21
Alternative Names: IM-1021; ZPC-21Latest Information Update: 31 Oct 2024
Price :
$50 *
At a glance
- Originator Zentalis Pharmaceuticals
- Developer Immunome; Zentalis Pharmaceuticals
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Oct 2024 Zentalis Pharmaceuticals announces intention to submit IND application to the FDA in Solid tumours in first quarter of 2025
- 29 Oct 2024 Pharmacodynamics data from a preclinical trial in cancer released by Immunome
- 23 Oct 2024 Pharmacodynamics data from preclinical trial in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)